Antitumor Effects of a Small Artificial RNA Sequence in Malignant Pleural Mesothelioma Through Suppression of Cell Cycle-Related Transcriptional Programs

Background/Objectives: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a poor prognosis and limited therapeutic options. Small RNA-based therapeutics may provide a means of simultaneously modulating multiple oncogenic pathways. We screened candidate small RNAs for antitumor activity in MPM and investigated the molecular basis of the response to the selected sequence. We aimed to identify a small RNA with reproducible antitumor activity in human mesothelioma cells and to define the signaling and transcriptional programs associated with its activity. Methods: Candidate small RNAs were transfected into three human mesothelioma cell lines (H2052, H2452, and H28). Cell viability and proliferation were assessed by WST-8 and BrdU incorporation assays. Intracellular signaling was examined using dual-luciferase reporters, and RNA sequencing with gene set enrichment analysis (GSEA) was used to characterize transcriptional changes. Results: Among the tested RNAs, the small artificial sequence (SAS) most consistently reduced cell viability and significantly suppressed proliferation in all three cell lines. Untreated mesothelioma cells showed prominent enrichment of E2F Targets compared with normal lung tissue, whereas SAS treatment suppressed E2F-associated cell-cycle programs and significantly reduced BrdU incorporation, consistent with inhibition of G1/S cell-cycle progression. SAS also reduced AP1 and SRE activities in H2452 cells but not in H2052 cells, indicating cell line-dependent modulation of MAPK-related signaling. SAS also induced interferon- and inflammatory response gene sets, with particularly strong cytokine induction observed after phosphorothioate (PS) modification of the passenger strand. Conclusions: SAS exerted reproducible antitumor effects in human mesothelioma cells, with suppression of cell proliferation and E2F-associated cell-cycle programs as the most consistent findings. These results support further investigation of SAS in MPM, although its therapeutic efficacy remains to be established in vivo.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-11-17
DOI
https://doi.org/10.3390/ph19111831
Primary Topic
Occupational and environmental lung diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Antitumor Effects of a Small Artificial RNA Sequence in Malignant Pleural Mesothelioma Through Suppression of Cell Cycle-Related Transcriptional Programs

Yuhki Yokoyama, Toshiyuki Minami, Takashi Kijima, Hiroyuki Yamamoto et al.
Pharmaceuticals
Occupational and environmental lung diseases
article

Antitumor Effects of a Small Artificial RNA Sequence in Malignant Pleural Mesothelioma Through Suppression of Cell Cycle-Related Transcriptional Programs

Yuhki Yokoyama, Toshiyuki Minami, Takashi Kijima, Hiroyuki Yamamoto, Kunimitsu Kawahara, Shihori Kouda, Akira Inoue, Hirofumi Yamamoto, Hidekazu Takahashi, Yoshihiro Morimoto, MANAMI TSUJIMOTO, Satoshi Shibata, Kota Miwa, Risa Uchida, Satoshi Bando
article en

Abstract

Background/Objectives: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a poor prognosis and limited therapeutic options. Small RNA-based therapeutics may provide a means of simultaneously modulating multiple oncogenic pathways. We screened candidate small RNAs for antitumor activity in MPM and investigated the molecular basis of the response to the selected sequence. We aimed to identify a small RNA with reproducible antitumor activity in human mesothelioma cells and to define the signaling and transcriptional programs associated with its activity. Methods: Candidate small RNAs were transfected into three human mesothelioma cell lines (H2052, H2452, and H28). Cell viability and proliferation were assessed by WST-8 and BrdU incorporation assays. Intracellular signaling was examined using dual-luciferase reporters, and RNA sequencing with gene set enrichment analysis (GSEA) was used to characterize transcriptional changes. Results: Among the tested RNAs, the small artificial sequence (SAS) most consistently reduced cell viability and significantly suppressed proliferation in all three cell lines. Untreated mesothelioma cells showed prominent enrichment of E2F Targets compared with normal lung tissue, whereas SAS treatment suppressed E2F-associated cell-cycle programs and significantly reduced BrdU incorporation, consistent with inhibition of G1/S cell-cycle progression. SAS also reduced AP1 and SRE activities in H2452 cells but not in H2052 cells, indicating cell line-dependent modulation of MAPK-related signaling. SAS also induced interferon- and inflammatory response gene sets, with particularly strong cytokine induction observed after phosphorothioate (PS) modification of the passenger strand. Conclusions: SAS exerted reproducible antitumor effects in human mesothelioma cells, with suppression of cell proliferation and E2F-associated cell-cycle programs as the most consistent findings. These results support further investigation of SAS in MPM, although its therapeutic efficacy remains to be established in vivo.

PharmaceuticalsVol. 19(11)
Osaka Gakuin University (JP), Hyogo Medical University (JP), Osaka Prefectural Medical Center (JP), Ikeda Municipal Hospital (JP), The University of Osaka (JP)
Japan Society for the Promotion of Science
Good health and well-being
Occupational and environmental lung diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon